Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Cordon-Cardo, G. Dalbagni, G. Sáez, M. Oliva, Zuo‐Feng Zhang, J. Rosai, V. Reuter, A. Pellicer (1994)
p53 mutations in human bladder cancer: Genotypic versus phenotypic patternsInternational Journal of Cancer, 56
S. Bodner, J. Minna, S. Jensen, D. D'Amico, D. D'Amico, D. Carbone, T. Mitsudomi, J. Fedorko, D. Buchhagen, M. Nau, A. Gazdar, R. Linnoila (1992)
Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.Oncogene, 7 4
D. Lohmann, C. Ruhri, M. Schmitt, H. Graeff, H. Hofler (1993)
Accumulation of p53 Protein as an Indicator for p53 Gene Mutation in Breast Cancer: Occurrence of False‐Positives and False‐NegativesDiagnostic Molecular Pathology, 2
M. Oren (1992)
p53: the ultimate tumor suppressor gene?The FASEB Journal, 6
D. Sidransky, A. Eschenbach, Y. Tsai, P. Jones, I. Summerhayes, F. Marshall, Meera Paul, Pearl Green, S. Hamilton, P. Frost, B. Vogelstein (1991)
Identification of p53 gene mutations in bladder cancers and urine samples.Science, 252 5006
P. Lianes, I. Orlow, Zuo‐Feng Zhang, M. Oliva, Á. Sarkis, V. Reuter, C. Cordon-Cardo (1994)
Altered patterns of MDM2 and TP53 expression in human bladder cancer.Journal of the National Cancer Institute, 86 17
C. Spruck, W. Rideout, A. Olumi, P. Ohneseit, A. Yang, Y. Tsai, P. Nichols, T. Horn, G. Hermann, K. Steven (1993)
Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage.Cancer research, 53 5
J. Ash (1940)
Epithelial Tumors of the Bladder1The Journal of Urology, 44
C. Miller, Koeffler Hp (1993)
P53 mutations in human cancer.Leukemia, 7 Suppl 2
C. Cordon-Cardo, D. Wartinger, D. Petrylak, G. Dalbagni, W. Fair, Z. Fuks, V. Reuter (1992)
Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer.Journal of the National Cancer Institute, 84 16
T. Lehman, W. Bennett, R. Metcalf, J. Welsh, J. Ecker, R. Modali, S. Ullrich, J. Romano, E. Appella, J. Testa, B. Gerwin, C. Harris (1991)
p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.Cancer research, 51 15
T. Uchida, C. Wada, H. Ishida, C. Wang, S. Egawa, E. Yokoyama, T. Kameya, K. Koshiba (1995)
p53 mutations and prognosis in bladder tumors.The Journal of urology, 153 4
C. Logothetis, H. Xu, J. Ro, S. Hu, A. Sahin, N. Ordóñez, W. Benedict (1992)
Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer.Journal of the National Cancer Institute, 84 16
H. Miyamoto, T. Shuin, S. Torigoe, Y. Iwasaki, Y. Kubota (1995)
Retinoblastoma gene mutations in primary human bladder cancer.British Journal of Cancer, 71
A. Thompson, T. Anderson, A. Condie, J. Prosser, U. Chetty, David Carter, H. Evans, C. Steel (1992)
p53 allele losses, mutations and expression in breast cancer and their relationship to clinico‐pathological parametersInternational Journal of Cancer, 50
H. Gilbert, J. Logan, A. Kagan, H. Friedman, J. Cove, M. Fox, T. Muldoon, Y. Lonni, J. Rowe, J. Cooper, H. Nussbaum, P. Chan, A. Rao, A. Starr (1978)
The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histologic grading.The Journal of urology, 119 4
K. Kawajiri, J. Watanabe, H. Eguchi, S. Hayashi (1995)
Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility.Pharmacogenetics, 5 Spec No
Jonathan Horowitz, Sang Park, Emil Bogenmann, Jeng Cheng, Jeng Cheng, D. Yandell, F. Kaye, John Minna, T. Dryja, Robert Weinberg (1990)
Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells.Proceedings of the National Academy of Sciences of the United States of America, 87 7
G. Dalbagni, J. Presti, V. Reuter, Zuo‐Feng Zhang, Á. Sarkis, W. Fair, C. Cordon-Cardo (1993)
Molecular Genetic Alterations of Chromosome 17 and p53 Nuclear Overexpression in Human Bladder CancerDiagnostic Molecular Pathology, 2
D. Adam, A. Thompson (1994)
Correlation between p53 mutations and antibody staining in breast carcinoma.The British journal of surgery, 81 7
Douglas Bell, Claudia Thompson, Jack Taylor, Chris Miller, Frederica Perera, Ling Hsieh, G. Lucier (1992)
Genetic monitoring of human polymorphic cancer susceptibility genes by polymerase chain reaction: application to glutathione transferase mu.Environmental Health Perspectives, 98
D. Esrig, D. Elmajian, S. Groshen, J. Freeman, J. Stein, Su‐Chiu Chen, P. Nichols, D. Skinner, P. Jones, R. Cote (1994)
Accumulation of nuclear p53 and tumor progression in bladder cancer.The New England journal of medicine, 331 19
Á. Sarkis, G. Dalbagni, C. Cordon-Cardo, Zuo‐Feng Zhang, J. Sheinfeld, W. Fair, H. Herr, V. Reuter (1993)
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.Journal of the National Cancer Institute, 85 1
C. Fleming, R. Persad, A. Kaisary, P. Smith, A. Adedoyin, J. Porter, G. Wilkinson, R. Branch (1994)
Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer.Pharmacogenetics, 4 4
Carly Leonard, C. Canman, M. Kastan (1995)
The role of p53 in cell-cycle control and apoptosis: implications for cancer.Important advances in oncology
W. Kusser, Xili Miao, B. Glickman, Joan Friedland, N. Rothman, G. Hemstreet, John Mellot, D. Swan, P. Schulte, R. Hayes (1994)
p53 mutations in human bladder cancerEnvironmental and Molecular Mutagenesis, 24
S. Kroft, R. Oyasu (1994)
Urinary bladder cancer: mechanisms of development and progression.Laboratory investigation; a journal of technical methods and pathology, 71 2
H. Anton-Culver (1991)
Smoking and other risk factors associated with the stage and age of diagnosis of colon and rectum cancers.Cancer detection and prevention, 15 5
E. Giovannucci, G. Colditz, M. Stampfer, D. Hunter, B. Rosner, W. Willett, F. Speizer (1994)
A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. women.Journal of the National Cancer Institute, 86 3
K. Fujimoto, Yukishige Yamada, E. Okajima, T. Kakizoe, H. Sasaki, Takashi Sugimura, M. Terada (1992)
Frequent association of p53 gene mutation in invasive bladder cancer.Cancer research, 52 6
J. Wolff, R. Stephenson, G. Jakse, F. Habib (1994)
Retinoblastoma and p53 genes as prognostic indicators in urological oncology.Urologia internationalis, 53 1
Y. Umekita, Keiko Kobayashi, T. Saheki, H. Yoshida (1994)
Nuclear Accumulation of p53 Protein Correlates with Mutations in the p53 Gene on Archival Paraffin‐embedded Tissues of Human Breast CancerJapanese Journal of Cancer Research : Gann, 85
Borland Rn, C. Brendler, W. Isaacs (1992)
Molecular biology of bladder cancer.Hematology/oncology clinics of North America, 6 1
R. Takahashi, T. Hashimoto, Hong‐Ji Xu, Shixue Hu, T. Matsui, T. Miki, HILtNE BIGO-MARSHALL, S. Aaronson, W. Benedict (1991)
The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells.Proceedings of the National Academy of Sciences of the United States of America, 88
A. Kaisary, P. Smith, Evelyne Jaczq, C. Mcallister, G. Wilkinson, W. Ray, R. Branch (1987)
Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.Cancer research, 47 20
C. Cordon-Cardo, G. Dalbagni, Á. Sarkis, V. Reuter (1994)
Genetic alterations associated with bladder cancer.Important advances in oncology
E. Heineman, S. Zahm, J. Mclaughlin, J. Vaught (1994)
Increased risk of colorectal cancer among smokers: Results of a 26‐year follow‐up of us veterans and a reviewInternational Journal of Cancer, 59
D. Bell, Jack Taylor, D. Paulson, C. Robertson, J. Mohler, G. Lucier (1993)
Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer.Journal of the National Cancer Institute, 85 14
R. Persad, C. Fleming, H. Chern, Lesnick Tg, C. Collins, P. Smith, A. Schwartz, A. Adedoyin, M. Romkes, G. Wilkinson, R. Branch (1997)
Environmental procarcinogen hypothesis of bladder cancer in humans: Dapsone hydroxylation as a susceptibility risk factor for aggressive bladder cancer.Urologic oncology, 3 1
p53 and Rbgene mutations are intermediate biomarkers useful for the prediction of neoplastic progression in bladder cancers. Previously, we have shown that low CYP3A activity, measured by dapsone N-hydroxylation, and high CYP2D6 activity, assessed by debrisoquine 4-hydroxylation, were significant susceptibility risk factors in developing aggressive bladder cancer. However, no information is available about the relationship between drug/xenobiotic metabolizing enzyme activities and p53/Rbmutations that may suggest mechanisms of bladder carcinogenesis. We evaluated in vivoCYP3A activity by the dapsone recovery ratio (DPRR), CYP2D6 activity by the debrisoquine recovery ratio (DBRR), CYP2C19 activity by the mephenytoin R/S ratio (RSR), N-acetyltransferase activity by the monoacetyl dapsone to dapsone ratio and glutathione-S-transferase M1 (GSTM1) genotype by PCR. In immunohistochemical studies of bladder tumor tissue, over expression of p53 protein was detected with antibody pAb1801 and loss of Rbprotein expression was evaluated with antibody PMG3–245 in patients with transitional cell carcinoma of the bladder. Low CYP3A activity was significantly associated with over expression of or mutated p53 protein (P< 0.05). High CYP2D6 activity (within the extensive metabolizer group) was significantly associated with loss of expression of or mutated Rbprotein (P< 0.05). Positive p53 staining also predicted aggressive bladder cancer histopathology (P< 0.05, odds ratio 2.9), and the lowest tertile of DPRR predicted p53 positivity (P< 0.01, odds ratio 3.9 comparing means of lower tertile versus upper tertile of DPRR). These selective associations are consistent with the hypothesis that an environmental pro-carcinogen fails to be detoxified by CYP3A which may preferentially induce p53mutations, whereas, an alternative pro-carcinogen that may be activated by CYP2D6, may selectively induce Rbmutations.
Carcinogenesis – Oxford University Press
Published: May 1, 1996
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.